Impact of bone marrow fibrosis grade in postpolycythemia vera and postessential thrombocythemia myelofibrosis: A study of the MYSEC group Par MarcGuevreguian|2021-03-23T10:37:18+01:00octobre 7th, 2019| Lire la suite
Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma Par MarcGuevreguian|2021-03-23T11:01:46+01:00septembre 28th, 2019| Lire la suite
A First-in-Human Phase I Study of INVAC-1 Par MarcGuevreguian|2021-03-23T09:46:38+01:00septembre 26th, 2019| Lire la suite
Adjuvant ipilimumab versus placebo after complete resection of stage III melanoma Par MarcGuevreguian|2021-03-23T11:26:14+01:00septembre 23rd, 2019| Lire la suite
Pazopanib or methotrexate-vinblastine combination chemotherapy in adult patients… Par MarcGuevreguian|2021-03-23T11:08:19+01:00septembre 23rd, 2019| Lire la suite
Adjuvant ipilimumab versus placebo after complete resection of stage III melanoma Par MarcGuevreguian|2021-03-23T11:04:45+01:00septembre 23rd, 2019| Lire la suite
IPH4102, a first-in-class anti-KIR3DL2 monoclonal antibody in patients with refractory cutaneous T cell lymphoma: An international multicentre phase 1 trial Par MarcGuevreguian|2021-03-23T10:25:51+01:00août 23rd, 2019| Lire la suite
Safety and efficacy findings from the open-label, multicenter, phase 3b Par MarcGuevreguian|2021-03-23T09:54:43+01:00juillet 30th, 2019| Lire la suite
Ponatinib efficacy and safety in Philadelphia chromosome–positive leukemia Par MarcGuevreguian|2021-03-23T10:22:16+01:00juillet 26th, 2019| Lire la suite
Checkpoint inhibitor treatment induces an increase in HbA1c in nondiabetic patients Par MarcGuevreguian|2021-03-23T11:12:47+01:00juin 29th, 2019| Lire la suite
